Low-Dose Naltrexone for Complex Regional Pain Syndrome
This study is testing if low-dose naltrexone (LDN) can help reduce pain in people with Complex Regional Pain Syndrome (CRPS). You might be able to join if you are between 18 and 70 years old, have CRPS in an arm or leg for at least one year, and meet specific diagnostic criteria (Budapest criteria). You must also be on stable treatment for CRPS for at least one month and not be taking opioid pain medications. Participants will receive either LDN or a sugar pill (placebo) for several weeks. The main goal is to see how much pain severity changes about 4 weeks after treatment ends. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 120 participants. You will be randomly assigned to receive either low-dose naltrexone or a placebo.
- What's involved
- You will attend in-person or virtual study visits and complete questionnaires for a period of several weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Pain severity will be measured approximately 4 weeks after the conclusion of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sean Mackey, MD, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Changes in pain severityApproximately 4 weeks after conclusion of treatment.
Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine